Literature DB >> 7441820

Synthesis, stability, and cleavage of Newcastle disease virus glycoproteins in the absence of glycosylation.

T G Morrison, D Simpson.   

Abstract

Polypeptides synthesized in Newcastle disease virus (NDV)-infected CHO cells in the absence of glycosylation were characterized. Incorporation of either [3H]mannose of [3H]glucosamine into NDV polypeptides was inhibited to greater than 99% by the antibiotic tunicamycin. Under these conditions, infected cells synthesized proteins which comigrated on polyacrylamide gels with the viral L protein, nucleocapsid protein, membrane protein, and a polypeptide with a molecular weight of 55,000 (P55). These cells did not synthesize polypeptides with the size of the hemagglutinin-neuraminidase (HN) protein or the fusion (F0) protein. They did, however, synthesize new polypeptides with molecular weights of 75,000 (P75), 67,000 (P67), and 52,000 (P52). Peptide analysis revealed that P75 was a host cell protein whose synthesis is enhanced by tunicamycin. P67 corresponded to the unglycosylated forms of the glycoproteins were found to be relatively stable in infected cells. P55, previously thought to correspond to the cleaved form of F0, was found to be a unique viral protein which is associated with intracellular nucleocapsid structures.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7441820      PMCID: PMC353628     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

1.  Identification of biological activities of paramyxovirus glycoproteins. Activation of cell fusion, hemolysis, and infectivity of proteolytic cleavage of an inactive precursor protein of Sendai virus.

Authors:  A Scheid; P W Choppin
Journal:  Virology       Date:  1974-02       Impact factor: 3.616

2.  Isolation of paramyxovirus glycoproteins. Association of both hemagglutinating and neuraminidase activities with the larger SV5 glycoprotein.

Authors:  A Scheid; L A Caliguiri; R W Compans; P W Choppin
Journal:  Virology       Date:  1972-12       Impact factor: 3.616

3.  Efficient translation of tobacco mosaic virus RNA and rabbit globin 9S RNA in a cell-free system from commercial wheat germ.

Authors:  B E Roberts; B M Paterson
Journal:  Proc Natl Acad Sci U S A       Date:  1973-08       Impact factor: 11.205

4.  The cell-free synthesis and assembly of viral specific polypeptides into TMV particles.

Authors:  B E Roberts; B M Paterson; R Sperling
Journal:  Virology       Date:  1974-05       Impact factor: 3.616

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Selective inhibition of Newcastle disease virus-induced glycoprotein synthesis by D-glucosamine hydrochloride.

Authors:  A C Samson; C F Fox
Journal:  J Virol       Date:  1974-04       Impact factor: 5.103

7.  Isolation and properties of Newcastle disease virus nucleocapsid.

Authors:  D W Kingsbury; R W Darlington
Journal:  J Virol       Date:  1968-03       Impact factor: 5.103

8.  Ribonucleic acid synthesis of vesicular stomatitis virus. I. Species of ribonucleic acid found in Chinese hamster ovary cells infected with plaque-forming and defective particles.

Authors:  M Stampfer; D Baltimore; A S Huang
Journal:  J Virol       Date:  1969-08       Impact factor: 5.103

9.  Tunicamycin, a new antibiotic. I. Isolation and characterization of tunicamycin.

Authors:  A Takatsuki; K Arima; G Tamura
Journal:  J Antibiot (Tokyo)       Date:  1971-04       Impact factor: 2.649

10.  Inhibition of glycosylation of the influenza virus hemagglutinin.

Authors:  R T Schwarz; H D Klenk
Journal:  J Virol       Date:  1974-11       Impact factor: 5.103

View more
  14 in total

1.  Topological and operational delineation of antigenic sites on the HN glycoprotein of Newcastle disease virus and their structural requirements.

Authors:  K Nishikawa; T Morishima; T Toyoda; T Miyadai; T Yokochi; T Yoshida; Y Nagai
Journal:  J Virol       Date:  1986-12       Impact factor: 5.103

2.  Conformational changes in Newcastle disease virus fusion glycoprotein during intracellular transport.

Authors:  L W McGinnes; A Semerjian; T Morrison
Journal:  J Virol       Date:  1985-11       Impact factor: 5.103

3.  Maturation of the envelope glycoproteins of Newcastle disease virus on cellular membranes.

Authors:  J C Schwalbe; L E Hightower
Journal:  J Virol       Date:  1982-03       Impact factor: 5.103

4.  Mutation in the matrix protein of Newcastle disease virus can result in decreased fusion glycoprotein incorporation into particles and decreased infectivity.

Authors:  M E Peeples; M A Bratt
Journal:  J Virol       Date:  1984-07       Impact factor: 5.103

5.  Intracellular processing of the Newcastle disease virus fusion glycoprotein.

Authors:  T Morrison; L J Ward; A Semerjian
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

6.  RNA synthesis by Newcastle disease virus temperature-sensitive mutants in two RNA-negative complementation groups.

Authors:  M E Peeples; L L Rasenas; M A Bratt
Journal:  J Virol       Date:  1982-06       Impact factor: 5.103

7.  Structural and functional characterization of Newcastle disease virus polycistronic RNA species.

Authors:  A Wilde; T Morrison
Journal:  J Virol       Date:  1984-07       Impact factor: 5.103

8.  Biochemical study of the Feline Herpesvirus 1. Identification of glycoproteins by affinity.

Authors:  D Fargeaud; C B Jeannin; F Kato; G Chappuis
Journal:  Arch Virol       Date:  1984       Impact factor: 2.574

9.  UV irradiation analysis of complementation between, and replication of, RNA-negative temperature-sensitive mutants of Newcastle disease virus.

Authors:  M E Peeples; M A Bratt
Journal:  J Virol       Date:  1982-03       Impact factor: 5.103

10.  Monoclonal antibodies to hemagglutinin-neuraminidase and fusion glycoproteins of Newcastle disease virus: relationship between glycosylation and reactivity.

Authors:  L Long; D Portetelle; J Ghysdael; M Gonze; A Burny; G Meulemans
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.